These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21431303)

  • 1. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience.
    Thairu N; Kiriakidis S; Dawson P; Paleolog E
    Angiogenesis; 2011 Sep; 14(3):223-34. PubMed ID: 21431303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience.
    Khong TL; Larsen H; Raatz Y; Paleolog E
    Angiogenesis; 2007; 10(4):243-58. PubMed ID: 17805984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Collins TS; Hurwitz HI
    Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritis.
    Schoettler N; Brahn E
    Curr Opin Investig Drugs; 2009 May; 10(5):425-33. PubMed ID: 19431075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
    Bodoky G
    Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF as a therapeutic target in cancer.
    Ferrara N
    Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
    Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
    Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in colorectal cancer: current and future directions.
    Yeung Y; Tebbutt NC
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
    Mulder K; Scarfe A; Chua N; Spratlin J
    Expert Opin Biol Ther; 2011 Mar; 11(3):405-13. PubMed ID: 21281258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
    Krämer I; Lipp HP
    J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of angiogenic factors in rheumatoid arthritis.
    Azizi G; Boghozian R; Mirshafiey A
    Int J Rheum Dis; 2014 May; 17(4):369-83. PubMed ID: 24467605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
    Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.